REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN
4CPS-226
CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS?
4CPS-225
HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs)
4CPS-224
IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS
4CPS-223
BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS
4CPS-222
HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA
4CPS-221
ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE
4CPS-220
COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS.
4CPS-219
AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT
4CPS-218
TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS
4CPS-217
THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION
4CPS-216
OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH'S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT
4CPS-215
DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS.
4CPS-120
ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT»
4CPS-214
REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER
